H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI ±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study

Condition:   Advanced HR+ HER2 Negative Breast Carcinoma Intervention:   Drug: Enituzumab injection+Abesili tablets+Anastrozole tablets Sponsor:   Tianjin Medical University Cancer Institute and Hospital Recruiting

Source: ClinicalTrials.gov - December 22, 2021 Category: Research Source Type: clinical trials